Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

The Department of Cardiothoracic Surgery is a recognized leader in heart, lung and esophagus surgery. Our experience with complex cardiothoracic issues and knowledge of the latest advances have helped to establish NewYork-Presbyterian|Weill Cornell Medicine as a major referral center for cardiovascular and thoracic patients from around the world.

Cardiothoracic surgery group photo

Cardiac Surgery

The Division of Cardiac Surgery provides expert care to patients who need:

  • Coronary artery bypass surgery
  • Valve repair/replacement
  • Surgery for adult congenital heart disease
  • Minimally Invasive Heart Surgery
  • Ventricular Assist Devices (VADs)
Learn More
Cardiac Surgery team

Thoracic Surgery

The Division of Thoracic Surgery offers the most advanced surgical care for:

  • Lung and esophageal cancers
  • Emphysema
  • Hyperhidrosis
  • Hiatal hernia
  • Pericardial & Pleural Effusions
  • Thoracentesis
Learn More
Thoracic Surgery team

Why Choose Weill Cornell?

NewYork-Presbyterian & Weill Cornell Medicine - Cardiothoracic Surgery

New Advances

Simple Surgical Technique Associated with Significant Reduction in the Risk of Atrial Fibrillation After Cardiac Surgery

Mario Gaudino, MD

Dr. Mario Gaudino

 

A simple surgical technique during cardiac surgery was associated with a 56 percent reduction in the incidence of an irregular heart rhythm known as atrial fibrillation that can lead to stroke, with no added risks or side effects, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest that the method, called posterior left pericardiotomy, has significant potential for preventing prolonged hospital stays and the need for additional interventions and drugs to reduce the risk of strokes and heart failure associated with atrial fibrillation.

The study evaluated whether a posterior left pericardiotomy, a slit in the backside of the sac around the heart to drain excess fluid, could help prevent atrial fibrillation in patients who underwent cardiac surgeries. The randomized controlled trial was published Nov. 14 in The Lancet. Click here to read the full article.

Healthgrades specialty hospital rankings

Healthgrades rates NewYork-Presbtyerian and Weill Cornell as America's 50 Best Hospitals for Cardiac Surgery Award.  Superior Clinical Outcomes in Heart Bypass and Heart Valve Surgery.  

Healthgrades rates NewYork-Presbtyerian and Weill Cornell as America's 100 Best Hospitals for Cardiac Care Award.  Superior Clinical Outcomes in Heart Bypass, coronary interventional procedures, heart attack treatment, heart failure treatment, and heart valve surgery

Scientists Find a New Way to Reverse Immune Suppression in Tumors

two men posing for a photo

Drs. Vivek Mittal (left) and Dingcheng Gao

Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.

In the study, published Sept. 20 in Nature Cancer, the researchers identified a set of anti-immunosuppressive factors that can be secreted by cells called club cells that line airways in the lungs. They showed in a mouse model of lung cancer that these club cell factors inhibit highly potent immunosuppressive cells called myeloid-derived suppressor cells (MDSCs), which tumors often recruit to help them evade antitumor immune responses.

The inhibition of the MDSCs led to an increase in the number of antitumor T cells at the tumor site, and greatly improved the effectiveness of FDA approved PD1 immunotherapy. 

“These club cell-secreted factors are able to nullify immune suppressor cells that otherwise help tumors escape an effective antitumor response,” said co-senior author Dr. Vivek Mittal, director of research at the Neuberger Berman Lung Cancer Center and the Ford-Isom Research Professor of Cardiothoracic Surgery at Weill Cornell Medicine. “We’re excited by the possibility of developing these club cell factors into a cancer treatment.” Click Here to read the full article. 

TWIST - Designing an International Multi-center Trial

Evaluating therapeutic approaches through clinical research can be done at many different scales; some exploratory studies seek to enroll just a handful of participants at a single site while other ideas require a great deal more statistical power. Thankfully multi-center and international collaborations are an excellent source of that power! Join our Director Dr. Mario Gaudino on Tuesday August 17th for a look at his work and experience designing and running a trial that spans over 50 countries!

Presented by

Mario F. L. Gaudino, MD

Director, Joint Clinical Trials Office 

Time: Aug 17, 2021 02:00 PM Eastern Time (US and Canada)

Join Zoom Meeting

https://weillcornell.zoom.us/j/94207946257

Meeting ID: 942 0794 6257

One tap mobile

+16468769923,,94207946257# US (New York)

+13017158592,,94207946257# US (Washington DC)

Clinical Trials

The Cardiothoracic Surgery Department conducts a robust clinical trials program to evaluate the effectiveness of new treatments and medications that have the potential to improve the management of patients with heart, lung, and esophageal disease. The outcomes of heart, lung, and esophageal operations can be improved with technical innovations.

Current Clinical Trials

 

US News Cardiology & Heart Surgery Badge

The Weill Cornell Medicine's Department of Cardiothoracic Surgery is proud to partner with NewYork-Presbyterian, ranked #4 in Adult Cardiology & Heart Surgery Hospital in the nation and #1 in NYC by U.S. News and World Report.